Nghiên cứu hiệu quả và tính an toàn của Pegnano + Ribazol ở bệnh nhân viêm gan virus C mạn lần đầu điều trị

Study the efficay and safety ofPegnano plus Ribazol in treatement - nave patients with chronic hepatitis C, the standard of care therapy with Pegnano plus Ribazol according to the EASL guidelines for 31 naive - patients with chronic hepatitis C . The resuls showed that: SVR 74,2 percent (genotype 1: 69,2 percent (18/26); genotype 6: 100 percent (5/5) p0,05), discontinunuation of therapy in 3 patients due to NR, NULR, 3 patients due to VB, and 1 relapse. The drug was found to have some adverse effects: pyrexia (74,2 percent); fatigue (90,3 percent); headache, myalgia and arthralgia (32,3 percent); insomnia (55,8 percent); loss of appetit (32,3 percent); injection site inflammation 16,1 percent;. This adverse effects to occupe in first tree time injections, especially first time and to decrease in during therapy. The incidence of alopoecia, pruritus -rash, depression was lower and to late appear (17,81 percent, 6,4 percent, 3,2 percent). The adverse effects on the bone marrow to early appear affter primary month and increase in during therapy (Hb 12g/dL:58,6 percent , WBC 4G/L:76,7 percent, PLT150G/L: 38,7 percent). Adverse effects events generally in the range accepted and tolerability, disappearance after end therapy.